HK1138277A1 - Prophylactic and/or therapeutic agent for hyperlipemia - Google Patents
Prophylactic and/or therapeutic agent for hyperlipemiaInfo
- Publication number
- HK1138277A1 HK1138277A1 HK10104519.2A HK10104519A HK1138277A1 HK 1138277 A1 HK1138277 A1 HK 1138277A1 HK 10104519 A HK10104519 A HK 10104519A HK 1138277 A1 HK1138277 A1 HK 1138277A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- solvate
- salt
- prophylactic
- hyperlipemia
- therapeutic agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007087081 | 2007-03-29 | ||
PCT/JP2008/000788 WO2008120472A1 (ja) | 2007-03-29 | 2008-03-28 | 高脂血症の予防及び/又は治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1138277A1 true HK1138277A1 (en) | 2010-08-20 |
Family
ID=39808058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10104519.2A HK1138277A1 (en) | 2007-03-29 | 2010-05-10 | Prophylactic and/or therapeutic agent for hyperlipemia |
Country Status (12)
Country | Link |
---|---|
US (1) | US8426455B2 (zh) |
EP (2) | EP2433932A1 (zh) |
JP (1) | JP5275975B2 (zh) |
KR (1) | KR101420319B1 (zh) |
CN (1) | CN101627021B (zh) |
AT (1) | ATE549323T1 (zh) |
CA (1) | CA2680407C (zh) |
ES (1) | ES2380752T3 (zh) |
HK (1) | HK1138277A1 (zh) |
PT (1) | PT2141155E (zh) |
TW (1) | TWI407955B (zh) |
WO (1) | WO2008120472A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2559238T3 (es) * | 2009-09-28 | 2016-02-11 | Kowa Company, Ltd. | Agente para reducir el peso de la grasa visceral |
CN102977085B (zh) * | 2011-10-27 | 2015-07-29 | 四川大学 | 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途 |
JP6238460B2 (ja) * | 2012-09-27 | 2017-11-29 | 興和株式会社 | 脂質異常症治療剤 |
AU2014312931B2 (en) * | 2013-08-28 | 2019-09-19 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
LT3275438T (lt) | 2016-07-29 | 2021-03-25 | Kowa Company, Ltd. | Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką |
CN110809469A (zh) * | 2017-06-30 | 2020-02-18 | 兴和株式会社 | 医药组合物 |
WO2019004453A1 (ja) | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬品 |
KR102512494B1 (ko) * | 2017-06-30 | 2023-03-22 | 교와 가부시키가이샤 | 의약 |
US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
CA3085951C (en) * | 2017-12-21 | 2022-10-11 | Kowa Company, Ltd. | Methods of treatment of hypertriglyceridemia |
JP7356968B2 (ja) * | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
TWI829841B (zh) * | 2018-12-27 | 2024-01-21 | 日商興和股份有限公司 | 醫藥品 |
KR102289381B1 (ko) | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
DE19858789A1 (de) | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
KR20020005662A (ko) | 1999-04-09 | 2002-01-17 | 기따자또 이찌로 | 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약 |
CA2456732C (en) | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
DE10200138A1 (de) * | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
AU2003225027A1 (en) * | 2002-04-16 | 2003-11-03 | Merck And Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
BRPI0413991B8 (pt) * | 2003-09-03 | 2021-05-25 | Kowa Co | composto ativador de ppar e composição farmacêutica contendo o mesmo |
EP1714648A4 (en) | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | COMBINATION DRUGS |
US7790903B2 (en) * | 2005-02-23 | 2010-09-07 | Kowa Co., Ltd. | Process for production of optically active PPAR-activating compound and intermediate of the same |
JPWO2006090756A1 (ja) * | 2005-02-25 | 2008-07-24 | 杏林製薬株式会社 | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 |
AR054368A1 (es) | 2005-06-01 | 2007-06-20 | Takeda Pharmaceutical | Metodo para tratar hiperlipidemia |
-
2008
- 2008-03-20 TW TW097109834A patent/TWI407955B/zh active
- 2008-03-28 CA CA2680407A patent/CA2680407C/en not_active Expired - Fee Related
- 2008-03-28 PT PT08720655T patent/PT2141155E/pt unknown
- 2008-03-28 ES ES08720655T patent/ES2380752T3/es active Active
- 2008-03-28 EP EP11195053A patent/EP2433932A1/en not_active Withdrawn
- 2008-03-28 US US12/593,356 patent/US8426455B2/en active Active
- 2008-03-28 AT AT08720655T patent/ATE549323T1/de active
- 2008-03-28 KR KR1020097018191A patent/KR101420319B1/ko active IP Right Grant
- 2008-03-28 WO PCT/JP2008/000788 patent/WO2008120472A1/ja active Application Filing
- 2008-03-28 CN CN2008800033811A patent/CN101627021B/zh active Active
- 2008-03-28 JP JP2009507415A patent/JP5275975B2/ja active Active
- 2008-03-28 EP EP08720655A patent/EP2141155B1/en active Active
-
2010
- 2010-05-10 HK HK10104519.2A patent/HK1138277A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101627021B (zh) | 2012-11-28 |
EP2141155A4 (en) | 2010-05-19 |
WO2008120472A1 (ja) | 2008-10-09 |
ES2380752T3 (es) | 2012-05-18 |
TW200838510A (en) | 2008-10-01 |
US20100069433A1 (en) | 2010-03-18 |
JP5275975B2 (ja) | 2013-08-28 |
EP2141155B1 (en) | 2012-03-14 |
US8426455B2 (en) | 2013-04-23 |
KR20090129994A (ko) | 2009-12-17 |
TWI407955B (zh) | 2013-09-11 |
CA2680407C (en) | 2015-04-21 |
EP2141155A1 (en) | 2010-01-06 |
CA2680407A1 (en) | 2008-10-09 |
KR101420319B1 (ko) | 2014-07-16 |
CN101627021A (zh) | 2010-01-13 |
EP2433932A1 (en) | 2012-03-28 |
PT2141155E (pt) | 2012-05-23 |
ATE549323T1 (de) | 2012-03-15 |
JPWO2008120472A1 (ja) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1138277A1 (en) | Prophylactic and/or therapeutic agent for hyperlipemia | |
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
WO2007107470A3 (en) | Pyrazoles as 11-beta-hsd-1 | |
IL185277A0 (en) | Pharmaceutical compositions containing roflumilast for the treatment of diabetes | |
CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
EP1771188A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS, INSULINED DISEASES AND HYPERCHOLESTERINEMIA | |
CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
PT1789403E (pt) | Derivados de n-(fenil-oxazol-4-ilmetoximetil)-ciclo-hexilsuccinamida e compostos relacionados como ligandos dos ppar (receptores activados de proliferadores de peroxisomas) para o tratamento da hiperlipidemia e diabetes | |
EP2070540A4 (en) | DRUG COMPOSITION FOR THE TREATMENT OF DIABETES TYPE 2 AND CHRONIC NEOPATHY | |
WO2008053446A3 (en) | Benzoxazepine compounds, their preparation and use | |
MX2010003989A (es) | Composicion zibotentan que contiene mannitol y/o celulosa microcristalina. | |
EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
IL192415A0 (en) | Pharmaceutical composition for the treatment of nail diseases | |
TW200800954A (en) | Novel crystal modifications | |
EA200701615A1 (ru) | Новые лекарственные средства для лечения заболеваний дыхательных путей | |
CL2013001164A1 (es) | Composicion que contiene 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica; proceso de preparacion; tableta que la contiene; kit y uso en el tratamiento y prevencion de trastornos cardiovasculares. | |
WO2011098799A3 (en) | Respiratory disease treatment | |
WO2007047431A3 (en) | Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors | |
ZA200704104B (en) | A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer | |
CL2007002366A1 (es) | Sales maleato, tosilato, fumarato y oxalato de 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida; proceso de preparacion de dichas sales, utiles para el tratamiento de afecciones |